Related references
Note: Only part of the references are listed.The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
Eva Martinez-Garcia et al.
BLOOD (2011)
The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells
Lucia Lopez-Corral et al.
CLINICAL CANCER RESEARCH (2011)
The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors
Heidi Rye Hudlebusch et al.
CLINICAL CANCER RESEARCH (2011)
Clinical impact of chromosomal aberrations in multiple myeloma
H. Nahi et al.
JOURNAL OF INTERNAL MEDICINE (2011)
Clinical and biological features of t(4;14) multiple myeloma: a prospective study
Lionel Karlin et al.
LEUKEMIA & LYMPHOMA (2011)
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
Huadong Pei et al.
NATURE (2011)
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
Kai Neben et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
H. Avet-Loiseau et al.
LEUKEMIA (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Donna Reece et al.
BLOOD (2009)
FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma
Fabiola Quintero-Rivera et al.
CANCER GENETICS AND CYTOGENETICS (2009)
Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
Guido Bisping et al.
CLINICAL CANCER RESEARCH (2009)
Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma
Mark A. Dawson et al.
CLINICAL CANCER RESEARCH (2009)
FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14)
Thea K. Vatsveen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Jing Qing et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji K. Kumar et al.
MAYO CLINIC PROCEEDINGS (2009)
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
Mauricio Pineda-Roman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2008)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome
Olivier Decaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
G. Schilling et al.
LEUKEMIA (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Multiple myeloma: Charging toward a bright future
Jed A. Katzel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma
Hong Chang et al.
LEUKEMIA RESEARCH (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
A. K. Stewart et al.
LEUKEMIA (2007)
PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells
Janelle Sharkey et al.
BLOOD (2007)
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
Wee J. Chng et al.
CANCER RESEARCH (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura et al.
BLOOD (2006)
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
Xiahua Xin et al.
CLINICAL CANCER RESEARCH (2006)
Receptor specificity of the fibroblast growth factor family - The complete mammalian FGF family
Xiuqin Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Suzanne Trudel et al.
BLOOD (2006)
Ploidy status rarely changes in myeloma patients at disease progression
WJ Chng et al.
LEUKEMIA RESEARCH (2006)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
MA Gertz et al.
BLOOD (2005)
Clinical outcomes in t(4;14) multiple myeloma: A chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance
W Jaksic et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A validated FISH trisony index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS
WJ Chng et al.
BLOOD (2005)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
SH Lee et al.
CLINICAL CANCER RESEARCH (2005)
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
JJ Keats et al.
BLOOD (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma
JL Paterson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB:: a molecular and genetic analysis of the chromosomal breakpoint
GR Boersma-Vreugdenhil et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
S Trudel et al.
BLOOD (2004)
Specific targeted therapy of chronic myelogenous leukemia with imatinib
MWN Deininger et al.
PHARMACOLOGICAL REVIEWS (2003)
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients
ON Onwuazor et al.
BLOOD (2003)
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
M Santra et al.
BLOOD (2003)
Fibroblast growth factors and their receptors in transitional cell carcinoma
NP Munro et al.
JOURNAL OF UROLOGY (2003)
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
P Moreau et al.
BLOOD (2002)
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
H Avet-Loiseau et al.
BLOOD (2002)
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
H Avet-Loiseau et al.
BLOOD (2001)
The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance
R Fonseca et al.
BLOOD (2001)
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)
D Intini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma
J Shaughnessy et al.
BLOOD (2001)
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
D Ronchetti et al.
ONCOGENE (2001)
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy
R Fonseca et al.
LEUKEMIA (2001)
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells
ZH Li et al.
BLOOD (2001)
Share Paper
